Rigel Pharmaceuticals Inc (RIGL) fair value: what the stock is really worth
As of Oct 15, 2026: fair value of Rigel Pharmaceuticals Inc $95.16, price $47.25, upside +101.4%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 15, 2026.
How to read this chart
60‑month range $6.70 – $50.96 · fair‑value band $63.82 – $141.70 · the $47.25 price screens below the $95.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 15, 2026.
Follow Rigel Pharmaceuticals in your weekly email
Every Wednesday you see whether Rigel Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
Show moreShow less
The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome.
The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation.
Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Stock analysis
Rigel Pharmaceuticals Inc (RIGL) currently trades at $47.25, while our model-based Fair Value estimate is $95.16, implying the stock looks roughly 50.3% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $912.85 per share, and 22 of the 23 models we run sit above the $47.25 price.
Bear case: the Asset-Based group reads lowest at $14.04, and 1 of the 23 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $63.82 (bear) to $141.70 (bull), the price of $47.25 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Rigel Pharmaceuticals Inc reported revenue of $294M in FY2025 versus $149M in FY2021, a compound +18.5%/yr. Reported net income was $367M in FY2025.
Key figures
Market cap $925M · P/E ratio 2.8 · P/S ratio 3.54 · EPS (TTM) $16.64 · Net margin 125% · Return on equity 127% · Return on assets (EBIT) −5.4% · Operating margin 30.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 60 out of 100 (medium confidence).
What moves the price
The share trades about 7% below its 52-week high and 86% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 101%, RIGL screens cheaper than that median.
Fair Value models
Bear$63.82Fair Value $95.16Bull$141.70
Price $47.25 · Upside +101.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($13.18 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.77/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+64.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.1%
Start year 2020 (pandemic). Over 10 years: +26.1% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.4%
’13
’14
’15
’16
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−26.7% (2020) → 42.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+15.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +0.4% a year for the price and +12.5% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Compare Rigel Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 604 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score70 · Top 25%
Fair Value upside+101.4% · Top 25%
Profitability
Return on equity (12 months)126.9% · Top 25%
Return on assets71.5% · Top 25%
Net margin (12 months)116.3% · Top 25%
Operating margin (12 months)30.0% · Top 25%
Growth and dividend
Revenue growth−22.6% · Bottom 25%
Balance sheet
Debt / equity0.06× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Rigel Pharmaceuticals Inc (RIGL) overvalued or undervalued?
As of Oct 15, 2026, our model estimates a fair value of $95.16 versus a price of $47.25, about +101% upside (undervalued).
What is the fair value of RIGL?
Our model-based fair value for Rigel Pharmaceuticals Inc is $95.16 (as of Oct 15, 2026), built from audited fundamentals. The current price: $47.25.
What is the quality score of RIGL?
Rigel Pharmaceuticals Inc has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rigel Pharmaceuticals Inc (RIGL)?
Our model-based price target is the fair value of $95.16 (as of Oct 15, 2026) from 23 valuation models. Cautious scenario $63.82, optimistic scenario $141.70. It is a calculation from audited fundamentals, not an analyst target.
What is the Rigel Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $95.16, about +101% upside versus a price of $47.25 (undervalued). Cautious scenario $63.82, optimistic scenario $141.70. The calculation is refreshed regularly with new filings.
What is the revenue of Rigel Pharmaceuticals Inc (RIGL)?
Rigel Pharmaceuticals Inc reported trailing-twelve-month revenue of about $277M (latest available figure, as of Oct 15, 2026).
What growth is priced into Rigel Pharmaceuticals Inc (RIGL)?
For today's price to be fair in a discounted-cash-flow model, Rigel Pharmaceuticals Inc would have to grow free cash flow by +2.8 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +22.1 % per year. As of Oct 15, 2026.
What discount rate (WACC) does the fair value of RIGL use?
Our models discount Rigel Pharmaceuticals Inc at 11.8 %: a base by market capitalisation (small), damped by beta 1.20, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Rigel Pharmaceuticals Inc that is +2.8 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Rigel Pharmaceuticals Inc (RIGL) delivered so far?
Over the past 5 years revenue at Rigel Pharmaceuticals Inc grew +22.1 % a year. The price currently implies +2.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Rigel Pharmaceuticals Inc (RIGL) growing?
The median revenue growth in the sector is +5.4 % a year. That is the yardstick for the growth priced into Rigel Pharmaceuticals Inc (+2.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Rigel Pharmaceuticals Inc (RIGL)?
The free-cash-flow yield on the price is 8.18 %: that much free cash flow Rigel Pharmaceuticals Inc produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Rigel Pharmaceuticals Inc (RIGL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rigel Pharmaceuticals Inc it is $95.16 per share (as of Oct 15, 2026), against a price of $47.25. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Rigel Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Oct 15, 2026, RIGL trades below its calculated fair value: price $47.25, fair value $95.16, a gap of about +101% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RIGL?
No. The price is what the market pays today ($47.25); the fair value is what the company's own numbers justify ($95.16). For Rigel Pharmaceuticals Inc the two are $47.91 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rigel Pharmaceuticals Inc worth?
The market values Rigel Pharmaceuticals Inc at about $925M (market capitalisation, as of Oct 15, 2026). Per share that is $47.25; our models calculate a fair value of $95.16 per share.
What do the bullish and bearish scenarios say about RIGL?
Our models span a range for Rigel Pharmaceuticals Inc: cautious scenario $63.82, base $95.16, optimistic $141.70 per share (as of Oct 15, 2026, price $47.25). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RIGL?
Rigel Pharmaceuticals Inc trades at a price-to-earnings ratio of 2.8 (as of Oct 15, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $95.16 is built from several models across several years. Other multiples: P/B 2.4, P/S 3.3, EV/EBITDA 10.1.
How solid is the balance sheet of Rigel Pharmaceuticals Inc (RIGL)?
Balance-sheet figures for Rigel Pharmaceuticals Inc (as of Oct 15, 2026): return on equity 126.9%, debt of 0.06 per unit of equity. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is RIGL from its 52-week high?
Rigel Pharmaceuticals Inc trades at $47.25, about 7% below its 52-week high of $50.96 and 86% above the low of $25.44 (as of Oct 15, 2026). Distance from the high says nothing about value: that is what the fair value of $95.16 is for.
Which stocks are comparable to Rigel Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rigel Pharmaceuticals Inc stock attractive at the current price?
The data as of Oct 15, 2026: price $47.25, calculated fair value $95.16 (+101%), Quality Score 70/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RIGL calculated?
We run Rigel Pharmaceuticals Inc through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $95.16, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.8 % above its aggregate fair value. Rigel Pharmaceuticals Inc currently trades 50 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rigel Pharmaceuticals Inc (RIGL)?
The closing price on Oct 15, 2026 was $47.25. Our model-based fair value is $95.16, about +101% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rigel Pharmaceuticals Inc right now?
The rarer combination: high quality (70/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case ($63.82). The market is more pessimistic than our downside scenario. A fairly wide model range ($63.82 to $141.70) leaves room in how you read the outcome.
Key figures of Rigel Pharmaceuticals Inc
How large is the market capitalisation of Rigel Pharmaceuticals Inc (RIGL)?
The market capitalisation of Rigel Pharmaceuticals Inc is $925M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rigel Pharmaceuticals Inc (RIGL)?
The price-to-sales ratio of Rigel Pharmaceuticals Inc is 3.54 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rigel Pharmaceuticals Inc (RIGL)?
Earnings per share at Rigel Pharmaceuticals Inc are $16.64 (price ÷ EPS = P/E 2.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Rigel Pharmaceuticals Inc (RIGL)?
The net margin of Rigel Pharmaceuticals Inc is 125% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Rigel Pharmaceuticals Inc (RIGL)?
The return on equity (ROE) of Rigel Pharmaceuticals Inc is 127% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rigel Pharmaceuticals Inc (RIGL)?
On an EBIT basis the return on assets of Rigel Pharmaceuticals Inc is −5.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rigel Pharmaceuticals Inc (RIGL)?
The operating margin of Rigel Pharmaceuticals Inc is 30.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rigel Pharmaceuticals Inc (RIGL)?
Revenue at Rigel Pharmaceuticals Inc is growing −22.6% versus a year earlier (3y avg +34.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Rigel Pharmaceuticals Inc (RIGL)?
Earnings per share at Rigel Pharmaceuticals Inc are growing −73.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Rigel Pharmaceuticals Inc (RIGL) carry?
The net debt of Rigel Pharmaceuticals Inc is $12.7M (fiscal year 2025, ≈ 0.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Rigel Pharmaceuticals Inc in the live analysis
One click puts Rigel Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Some data
Oct 15, 2026